The adjustment in price target by Needham, while maintaining a Buy rating, suggests a positive outlook on Surmodics' fundamentals but with a slightly moderated growth expectation. This could lead to a neutral short-term impact as the market digests the revised price target against the backdrop of ongoing confidence in the company's prospects.